Next Article in Journal
A Multi-Stage Human Factors and Comfort Assessment of Instrumented Insoles Designed for Use in a Connected Health Infrastructure
Next Article in Special Issue
Training the Future Leaders in Personalized Medicine
Previous Article in Journal
Patients’ Online Access to Their Primary Care Electronic Health Records and Linked Online Services: Implications for Research and Practice
Previous Article in Special Issue
“Cancer 2015”: A Prospective, Population-Based Cancer Cohort—Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic
Article Menu

Export Article

Open AccessReview
J. Pers. Med. 2015, 5(4), 470-486; doi:10.3390/jpm5040470

Assessing the Costs and Cost-Effectiveness of Genomic Sequencing

1
Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
2
Department of Pediatrics, Oregon Health and Science University, Portland, OR 97239, USA
3
Department of Public Health, Medical Decision Making and Health Technology Assessment, University for Health Sciences, Medical Informatics and Technology, Hall in Tirol 6060, Austria
4
Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115, USA
5
Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
6
Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Partners Personalized Medicine, Boston, MA 02115, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Scott T. Weiss
Received: 21 October 2015 / Revised: 1 December 2015 / Accepted: 4 December 2015 / Published: 10 December 2015
(This article belongs to the Special Issue Implementing Personalized Medicine in a Large Health Care System)
View Full-Text   |   Download PDF [440 KB, uploaded 10 December 2015]

Abstract

Despite dramatic drops in DNA sequencing costs, concerns are great that the integration of genomic sequencing into clinical settings will drastically increase health care expenditures. This commentary presents an overview of what is known about the costs and cost-effectiveness of genomic sequencing. We discuss the cost of germline genomic sequencing, addressing factors that have facilitated the decrease in sequencing costs to date and anticipating the factors that will drive sequencing costs in the future. We then address the cost-effectiveness of diagnostic and pharmacogenomic applications of genomic sequencing, with an emphasis on the implications for secondary findings disclosure and the integration of genomic sequencing into general patient care. Throughout, we ground the discussion by describing efforts in the MedSeq Project, an ongoing randomized controlled clinical trial, to understand the costs and cost-effectiveness of integrating whole genome sequencing into cardiology and primary care settings. View Full-Text
Keywords: whole genomic sequencing; whole exome sequencing; cost; cost-effectiveness whole genomic sequencing; whole exome sequencing; cost; cost-effectiveness
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Christensen, K.D.; Dukhovny, D.; Siebert, U.; Green, R.C. Assessing the Costs and Cost-Effectiveness of Genomic Sequencing. J. Pers. Med. 2015, 5, 470-486.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top